Yüklüyor......
Acceptability and feasibility of S-1 plus cisplatin adjuvant chemotherapy for completely resected non-small cell lung cancer: an open-label, single arm, multicenter, phase 2 trial
BACKGROUND: Although platinum-based chemotherapy is accepted as adjuvant chemotherapy for resectable advanced non-small cell lung cancer (NSCLC), its completion rate is low due to severe adverse events. S-1 plus cisplatin is associated with relatively low toxicity and an unimpaired quality of life,...
Kaydedildi:
| Yayımlandı: | J Thorac Dis |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
AME Publishing Company
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8107543/ https://ncbi.nlm.nih.gov/pubmed/34012573 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd-20-3293 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|